Drug Profile
Betamethasone butyrate propionate/maxacalcitol - Chugai Pharmaceutical/Maruho
Alternative Names: M 8010; M 801801; Marduox; Maxacalcitol/betamethasone butyrate propionateLatest Information Update: 06 Dec 2019
Price :
$50
*
At a glance
- Originator Chugai Pharmaceutical; Maruho
- Developer Maruho
- Class Analgesics; Anti-inflammatories; Antipruritics; Antipsoriatics; Calcium regulators; Dihydroxycholecalciferols; Fluorinated steroids; Glucocorticoids; Small molecules
- Mechanism of Action Steroid receptor antagonists; Vitamin D3 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Plaque psoriasis
Most Recent Events
- 01 Dec 2019 Chugai Pharmaceutical completes transfer of rights for betamethasone butyrate propionate/maxacalcitol to Maruho in Japan
- 02 Jul 2019 Chemical structure information added
- 30 Jan 2019 Chugai Pharmaceutical plans to transfer rights for Betamethasone butyrate propionate/maxacalcitol to Maruho from December 1, 2019